{"id":53988,"date":"2023-02-16T12:04:00","date_gmt":"2023-02-16T11:04:00","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/multiple-myeloma-market-size-and-trend-report-including-epidemiology-disease-management-pipeline-analysis-competitor-assessment-unmet-needs-clinical-trial-strategies-and-forecast-2021-2031-res\/"},"modified":"2023-02-16T12:04:00","modified_gmt":"2023-02-16T11:04:00","slug":"multiple-myeloma-market-size-and-trend-report-including-epidemiology-disease-management-pipeline-analysis-competitor-assessment-unmet-needs-clinical-trial-strategies-and-forecast-2021-2031-res","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/multiple-myeloma-market-size-and-trend-report-including-epidemiology-disease-management-pipeline-analysis-competitor-assessment-unmet-needs-clinical-trial-strategies-and-forecast-2021-2031-res\/","title":{"rendered":"Multiple Myeloma Market Size and Trend Report including Epidemiology, Disease Management, Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2021-2031 – ResearchAndMarkets.com"},"content":{"rendered":"
\n

DUBLIN–(BUSINESS WIRE)–The “Multiple Myeloma Market Size and Trend Report including Epidemiology, Disease Management, Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2021-2031”<\/a> drug pipelines has been added to ResearchAndMarkets.com’s<\/strong> offering.\n<\/p>\n

<\/a><\/p>\n

\nThis report includes an assessment of the disease epidemiology and 10-year patient-based forecast (PBF) across the eight major markets (8MM) for marketed and pipeline therapies with established mechanisms of action and cell therapies by class, including early to late clinical stage pipeline products, with a launch date assessment by market for multiple myeloma.\n<\/p>\n

\nIn addition to PBF sales data for the 8MM, this report contains sales forecast extrapolations for an additional seven geographical markets (7M), totaling 15 markets (15M). These sales forecast extrapolations leverage data on pharmaceutical sales and drug availability from the publisher’s World Markets Healthcare (WMH) and POLI Price Intelligence databases.\n<\/p>\n

\nThe report also analyzes the clinical and commercial landscapes of multiple myeloma, with pricing assumptions based on currently marketed products by class of cell therapies, accompanied with a transparent forecast methodology.\n<\/p>\n

\nAdditionally, the report evaluates indication-specific unmet needs, competitive assessment, and identifies key future players in the cell therapy market.\n<\/p>\n

\nGMCTs are well equipped to treat patients in later-line settings. Currently, gene-modified cell therapy (GMCT) agents are only available in 3L+ settings, with early-line settings dominated by combination therapies including anti-CD38 monoclonal antibodies and proteasome inhibitors, as well as patients being treated with autologous stem cell transplants.\n<\/p>\n

\nThe MM pipeline is dominated by CAR-T cells. The success of CAR-Ts in MM has fueled R&D investment into this class of therapy, with more CAR-Ts in development than all other cell and gene therapy (cell therapy) classes combined.\n<\/p>\n

\nThe MM cell therapy market is projected to reach $9.4 billion in 8MM peak sales. Using data from the publisher’s proprietary World Markets Healthcare (WMH) and Price Intelligence databases, sales forecasts for the 7M (Australia, South Korea, Belgium, Denmark, Switzerland, Israel, and Canada) assessed in this analysis show the overall MM market (cell therapies and established\/traditional therapies) is expected to reach $43.6 billion by 2031.\n<\/p>\n

\nUnmet needs in MM are likely to be partially addressed by cell therapies. GMCTs have good efficacy data in later-line settings in this indication. The presence of marketed and pipeline CAR-T cell therapies in the 3L+ setting addresses the unmet need of providing therapeutic options for heavily pre-treated patients\n<\/p>\n

\nKey Highlights<\/strong>\n<\/p>\n